(Q38777543)

6 September 2017

title

Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead (English)

1 reference

chronic renal insufficiency

6 September 2017

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Francesca Viazzi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Barbara Bonino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Francesca Cappadona

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

17 March 2016

1 reference

Internal and emergency medicine

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

627-635

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

RAAS inhibition and renal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

The renal effects of mineralocorticoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

The end of dual therapy with renin-angiotensin-aldosterone system blockade?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Role of remission clinics in the longitudinal treatment of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Sodium zirconium cyclosilicate in hyperkalemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Supramaximal dose of candesartan in proteinuric renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-016-1435-5

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis

1 reference

12 December 2020

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

12 December 2020

The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition

1 reference

12 December 2020

Aldosterone antagonists for preventing the progression of chronic kidney disease

1 reference

12 December 2020

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

12 December 2020

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

12 December 2020

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

12 December 2020

Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1007/S11739-016-1435-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984204%20AND%20SRC:MED&resulttype=core&format=json

release_y6c4pybpfbegxmwlbqlkcqll5u

1 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y6c4pybpfbegxmwlbqlkcqll5u

24 November 2022

mapped directly with Wikidata item

1 reference